UTHR
Price:
$345.63
Market Cap:
$15.38B
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unit...[Read more]
Industry
Biotechnology
IPO Date
1999-06-17
Stock Exchange
NASDAQ
Ticker
UTHR
According to United Therapeutics Corporation’s latest financial reports and current stock price. The company's current Enterprise Value is 14.52B. This represents a change of 34.47% compared to the average of 10.80B of the last 4 quarters.
The mean historical Enterprise Value of United Therapeutics Corporation over the last ten years is 7.06B. The current 14.52B Enterprise Value has changed 20.47% with respect to the historical average. Over the past ten years (40 quarters), UTHR's Enterprise Value was at its highest in in the June 2024 quarter at 13.31B. The Enterprise Value was at its lowest in in the June 2019 quarter at 3.76B.
Average
7.06B
Median
6.22B
Minimum
3.97B
Maximum
12.49B
Discovering the peaks and valleys of United Therapeutics Corporation Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 70.56%
Maximum Annual Enterprise Value = 12.49B
Minimum Annual Increase = -28.68%
Minimum Annual Enterprise Value = 3.97B
Year | Enterprise Value | Change |
---|---|---|
2023 | 9.78B | -21.68% |
2022 | 12.49B | 30.03% |
2021 | 9.61B | 41.90% |
2020 | 6.77B | 70.56% |
2019 | 3.97B | -8.07% |
2018 | 4.32B | -28.68% |
2017 | 6.05B | 15.13% |
2016 | 5.26B | -17.54% |
2015 | 6.38B | 6.88% |
2014 | 5.97B | 5.24% |
The current Enterprise Value of United Therapeutics Corporation (UTHR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
10.63B
5-year avg
8.52B
10-year avg
7.06B
United Therapeutics Corporation’s Enterprise Value is greater than Incyte Corporation (10.85B), less than Alnylam Pharmaceuticals, Inc. (33.42B), greater than Ultragenyx Pharmaceutical Inc. (5.53B), greater than Apellis Pharmaceuticals, Inc. (5.11B), greater than Replimune Group, Inc. (632.78M), greater than Nuvalent, Inc. (5.51B), greater than Ventyx Biosciences, Inc. (123.69M), greater than Ascendis Pharma A/S (6.58B), greater than MannKind Corporation (1.87B), greater than Larimar Therapeutics, Inc. (486.93M), greater than Day One Biopharmaceuticals, Inc. (1.01B), greater than Kiniksa Pharmaceuticals, Ltd. (1.69B), less than BeiGene, Ltd. (19.49B), greater than Akero Therapeutics, Inc. (1.56B), greater than Blueprint Medicines Corporation (6.16B), greater than Vaxcyte, Inc. (11.96B), greater than Legend Biotech Corporation (10.04B),
Company | Enterprise Value | Market cap |
---|---|---|
10.85B | $11.80B | |
33.42B | $31.68B | |
5.53B | $5.09B | |
5.11B | $5.00B | |
632.78M | $708.49M | |
5.51B | $5.59B | |
123.69M | $153.35M | |
6.58B | $6.83B | |
1.87B | $1.63B | |
486.93M | $513.64M | |
1.01B | $1.25B | |
1.69B | $1.78B | |
19.49B | $21.01B | |
1.56B | $1.83B | |
6.16B | $5.47B | |
11.96B | $12.45B | |
10.04B | $9.90B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like United Therapeutics Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like United Therapeutics Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is United Therapeutics Corporation's Enterprise Value?
What is the highest Enterprise Value for United Therapeutics Corporation (UTHR)?
What is the 3-year average Enterprise Value for United Therapeutics Corporation (UTHR)?
What is the 5-year average Enterprise Value for United Therapeutics Corporation (UTHR)?
How does the current Enterprise Value for United Therapeutics Corporation (UTHR) compare to its historical average?